Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype
- PMID: 1354447
- DOI: 10.1097/00002030-199207000-00008
Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype
Abstract
Objective: To determine the kinetics of decline of CD4+ lymphocytes in HIV-1-infected asymptomatic homosexual men.
Methods: CD4+ lymphocytes were enumerated in a cohort of 187 HIV-1-infected initially asymptomatic homosexual men seen at 3-month intervals over 5 years. During follow-up, 45 men progressed to AIDS (excluding cases presenting with Kaposi's sarcoma). Correlation between rate of CD4+ cell decline and presence of a particular HIV-1 biological phenotype was analysed in 43 participants.
Results: CD4+ cell counts declined slowly and continuously in HIV-1-seropositive men who remained asymptomatic during follow-up. A biphasic CD4+ cell count decline was observed in the group who developed AIDS: the decline was slow and steady (5.6 x 10(6)/l per month, similar to that observed in the asymptomatic group) until 18 months before AIDS diagnosis, but became three to five times faster thereafter. Rapid CD4+ cell decline was significantly related to syncytium-inducing, fast-replicating HIV-1 isolates; during the period of slow and steady CD4+ cell count decline, non-syncytium-inducing isolates were predominant.
Conclusions: At an average of 18 months preceding AIDS diagnosis, a three to fivefold increase in the rate of loss of CD4+ lymphocytes occurs, and may be related to the appearance of a more virulent HIV-1 phenotype.
Comment in
-
CD4 lymphocyte depletion prior to the development of AIDS.AIDS. 1992 Jul;6(7):735-6. doi: 10.1097/00002030-199207000-00018. AIDS. 1992. PMID: 1354451 No abstract available.
Similar articles
-
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.Ann Intern Med. 1993 May 1;118(9):681-8. doi: 10.7326/0003-4819-118-9-199305010-00004. Ann Intern Med. 1993. PMID: 8096374
-
Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS.J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Nov 1;19(3):254-9. doi: 10.1097/00042560-199811010-00007. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9803967
-
Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia.Am J Med. 1990 Dec;89(6):706-12. doi: 10.1016/0002-9343(90)90210-5. Am J Med. 1990. PMID: 1979205 Clinical Trial.
-
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.J Virol. 1989 May;63(5):2118-25. doi: 10.1128/JVI.63.5.2118-2125.1989. J Virol. 1989. PMID: 2564898 Free PMC article.
-
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression.J Virol. 1994 Jul;68(7):4400-8. doi: 10.1128/JVI.68.7.4400-4408.1994. J Virol. 1994. PMID: 7515972 Free PMC article.
Cited by
-
Serum 27E10 antigen: a new potential marker for staging HIV disease.Clin Exp Immunol. 1995 Aug;101(2):249-53. doi: 10.1111/j.1365-2249.1995.tb08346.x. Clin Exp Immunol. 1995. PMID: 7648708 Free PMC article.
-
Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression.J Virol. 2005 Jul;79(14):9006-18. doi: 10.1128/JVI.79.14.9006-9018.2005. J Virol. 2005. PMID: 15994794 Free PMC article.
-
Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.Curr Top Med Chem. 2014;14(13):1574-89. doi: 10.2174/1568026614666140827143541. Curr Top Med Chem. 2014. PMID: 25159167 Free PMC article. Review.
-
Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.J Virol. 2002 Jul;76(14):7187-202. doi: 10.1128/jvi.76.14.7187-7202.2002. J Virol. 2002. PMID: 12072518 Free PMC article. Clinical Trial.
-
Pharmacokinetics and pharmacodynamics of CD4-anchoring bi-functional fusion inhibitor in monkeys.Pharm Res. 2014 Mar;31(3):809-18. doi: 10.1007/s11095-013-1203-4. Epub 2013 Sep 25. Pharm Res. 2014. PMID: 24065594
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials